Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
2308 studies found for:    "Carcinoid tumor"
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Ramucirumab;   Drug: Somatostatin Analog
2 Withdrawn Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Condition: Malignant Carcinoid Tumor
Intervention: Drug: 90Y-SMT487
3 Not yet recruiting A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Condition: Small Bowel Carcinoid Tumor
Interventions: Drug: Ga-68-DOTA-TOC;   Device: Siemens PET/MR scanner;   Other: Standard Siemens Software;   Drug: LAR Octreotide
4 Completed
Has Results
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors
Intervention: Drug: Pasireotide (SOM230)
5 Active, not recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
6 Active, not recruiting
Has Results
A Study of Axitinib in Advanced Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Axitinib
7 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
8 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
9 Completed A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
10 Active, not recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
11 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
12 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
13 Active, not recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
14 Unknown  Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention: Drug: RAD001 (everolimus, Afinitor®)
15 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
16 No longer available Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Gallium-68 DOTATOC
17 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
18 Terminated 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Drug: 68Ga-DOTATOC PET
19 Completed Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Condition: Neuroendocrine Tumor
Intervention: Drug: Pazopanib
20 Completed EPO906 in Carcinoid and Other Neuroendocrine Tumors
Conditions: Carcinoid;   Neuroendocrine Tumors
Intervention: Drug: EPO906 epothilone B

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.